LYEL Smart Money
Lyell Immunopharma, Inc.
1W: +4.3%
1M: +3.9%
3M: -22.0%
YTD: -65.1%
1Y: -42.6%
3Y: -67.3%
5Y: -96.4%
$10.12
+0.81 (+8.70%)
Weekly Expected Move ±10.3%
$7
$8
$9
$10
$11
Credit Risk of going bust: higher than 72% of companies Debt: 13.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.23 (down 98%), Lyell Immunopharma, Inc. would be worth roughly what it owes.
Total debt $36.9M against a stock market value of $248.0M.
Distance to default 3.28 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $18.5M (short-term plus half of long-term), stock volatility 79.5%; Altman Z'' -16.22. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.23 (down 98%), Lyell Immunopharma, Inc. would be worth roughly what it owes.
Total debt $36.9M against a stock market value of $248.0M.
Distance to default 3.28 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $18.5M (short-term plus half of long-term), stock volatility 79.5%; Altman Z'' -16.22. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 202698
Institutions Holding
+14 vs prior
67.9%
Ownership
-27.61%
24
New
28
Increased
28
Reduced
9
Closed
👔 Insider Trades
25 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Aguirre Jarrad Mattieu | officer: chief medical officer | S-Sale | 422 | $8.63 | $4K | Filing |
| 2026-09-10 | Shook David | officer: chief medical officer | S-Sale | 500 | $12.70 | $6K | Filing |
| 2026-08-21 | Seely Lynn | officer: president and ceo | S-Sale | 9,589 | $15.54 | $149K | Filing |
| 2026-08-21 | Lee Gary K. | officer: chief scientific officer | S-Sale | 1,457 | $15.54 | $23K | Filing |
| 2026-08-21 | Hill Stephen J. | officer: chief operating officer | S-Sale | 989 | $15.54 | $15K | Filing |
| 2026-08-10 | Bulis Veronica Sanchez | officer: vp, corporate controller | S-Sale | 621 | $14.34 | $9K | Filing |
| 2026-08-10 | Seely Lynn | officer: president and ceo | S-Sale | 390 | $14.34 | $6K | Filing |
| 2026-08-10 | Hill Stephen J. | officer: chief operating officer | S-Sale | 89 | $14.34 | $1K | Filing |
| 2026-08-10 | Lee Gary K. | officer: chief scientific officer | S-Sale | 131 | $14.34 | $2K | Filing |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | J-J | 44,000 | $— | $0 | Filing |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | J-J | 38,500 | $— | $0 | Filing |
| 2026-07-17 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | S-Sale | 10 | $13.70 | $137 | Filing |
| 2026-07-16 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | S-Sale | 10 | $13.73 | $137 | Filing |
| 2026-06-29 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | J-J | 76,000 | $— | $0 | Filing |
| 2026-06-15 | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | J-J | 66,500 | $— | $0 | Filing |
| 2026-06-10 | Shook David | officer: chief medical officer | S-Sale | 1,977 | $12.64 | $25K | Filing |
| 2026-05-11 | Seely Lynn | officer: president and ceo | S-Sale | 388 | $18.91 | $7K | Filing |
| 2026-05-11 | Bulis Veronica Sanchez | officer: vp, corporate controller | S-Sale | 217 | $18.91 | $4K | Filing |
| 2026-05-11 | Hill Stephen J. | officer: chief operating officer | S-Sale | 89 | $18.92 | $2K | Filing |
| 2026-05-11 | Lee Gary K. | officer: chief scientific officer | S-Sale | 130 | $18.92 | $2K | Filing |
| 2026-02-11 | Seely Lynn | officer: president and ceo | S-Sale | 7,455 | $23.39 | $174K | Filing |
| 2026-02-11 | Lee Gary K. | officer: chief scientific officer | S-Sale | 1,671 | $23.39 | $39K | Filing |
| 2026-02-11 | Hill Stephen J. | officer: chief operating officer | S-Sale | 1,236 | $23.39 | $29K | Filing |
| 2026-02-10 | Lee Gary K. | officer: chief scientific officer | S-Sale | 147 | $23.12 | $3K | Filing |
| 2026-02-10 | Hill Stephen J. | officer: chief operating officer | S-Sale | 109 | $23.12 | $3K | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 3,247,162 | $46M | — | 2026-06-30 | Filing |
| GSK plc | 1,512,659 | $21M | — | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 786,774 | $11M | +68,619 | 2026-06-30 | Filing |
| Orland Properties Ltd | 754,698 | $11M | — | 2026-06-30 | Filing |
| BlackRock, Inc. | 724,342 | $10M | +532,522 | 2026-06-30 | Filing |
| Almitas Capital LLC | 581,407 | $8M | +3,600 | 2026-06-30 | Filing |
| Foresite Capital Management V, LLC | 476,386 | $7M | -692 | 2026-06-30 | Filing |
| MILLENNIUM MANAGEMENT LLC | 367,473 | $5M | -91,432 | 2026-06-30 | Filing |
| Opaleye Management Inc. | 344,025 | $5M | +264,928 | 2026-06-30 | Filing |
| venBio Partners LLC | 337,697 | $5M | — | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 310,636 | $4M | +143,656 | 2026-06-30 | Filing |
| Alphabet Inc. | 293,256 | $4M | — | 2026-06-30 | Filing |
| STATE STREET CORP | 185,322 | $3M | +112,800 | 2026-06-30 | Filing |
| HSG Holding Ltd | 152,299 | $2M | — | 2026-06-30 | Filing |
| RENAISSANCE TECHNOLOGIES LLC | 130,190 | $2M | +13,779 | 2026-06-30 | Filing |
| NORTHERN TRUST CORP | 118,500 | $2M | +88,220 | 2026-06-30 | Filing |
| Qube Research & Technologies Ltd | 110,531 | $2M | +55,421 | 2026-06-30 | Filing |
| Sixth Street Partners Management Company | 107,570 | $2M | +107,570 | 2026-06-30 | Filing |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 107,570 | $2M | +21,599 | 2026-06-30 | Filing |
| MARSHALL WACE, LLP | 106,300 | $1M | -42,216 | 2026-06-30 | Filing |